Skip to main content

Table 3 Course of liver enzymes in patients initially treated with D-penicillamine, grouped by treatment response

From: Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study

    Median UI/L (range) P value
ALT (UI/L) Baseline Responder 201 (23–514) .19
Non-responder 398 (173–582)
6 months Responder 122 (32–576) .26
Non-responder 236 (165–279)
12 months Responder 60 (20–178) ≤.001
Non-responder 91 (83–166)
24 months Responder 46 (14–76) ≤.001
Non-responder 205 (65–245)
>36 months Responder 36 (12–77) ≤.001
Non-responder 165 (91–377)
AST(UI/L) Baseline Responder 114 (27–227) .24
Non-responder 117 (72–205)
6 months Responder 60 (26–198) .23
Non-responder 94 (89–115)
12 months Responder 43 (22–74) .18
Non-responder 60 (47–60)
24 months Responder 38 (24–51) ≤.001
Non-responder 100 (85–114)
>36 months Responder 32 (20–61) .004
Non-responder 66 (40–76)
GGT(UI/L) Baseline Responder 68 (11–227) .54
Non-responder 74 (48–267)
6 months Responder 39 (14–119) .64
Non-responder 59 (49–65)
12 months Responder 27 (13–57) .19
Non-responder 42 (36–48)
24 months Responder 24 (12–44) .29
Non-responder 31 (31–32)
>36 months Responder 17 (12–40) .29
Non-responder 31 (25–41)